DDInter1087 DDInter899
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FT
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Lonafarnib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Lonafarnib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Lonafarnib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Lonafarnib {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Lonafarnib {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Lonafarnib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Loratadine
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Lonafarnib may lead to a major life threatening interaction when taken with Enzalutamide
Lonafarnib may lead to a major life threatening interaction when taken with Halofantrine